+44 20 8123 2220
info@marketpublishers.com

Orphan Drugs for Cancer: R&D and Market 2013-2023

https://marketpublishers.com/r/O4BD86BB26DEN.html
Date: July 2013
Pages: 179
Price: US$ 2,635.00 (Single User License)
ID: O4BD86BB26DEN

Abstracts

Orphan cancer drugs - new study shows you trends, R&D, and sales forecasts

What's the future of orphan medicines to treat cancers? Visiongain's new report gives you revenue predictions from 2013. There you explore results, R&D, opportunities, and potential sales.

Orphan drugs can be profitable. In our analysis you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You see the potential of treatments for rare cancers. Try our report now, helping you stay ahead.

Trends and revenue potentials of that rising pharma segment

Many opportunities remain for orphan medicines in cancer care. In our new study you assess treatments and their potential returns. You also investigate what affects their sales.

Read on, then, to explore that industry and see what its future market could be worth.

Forecasts 2013-2023 and other analyses - find commercial opportunities

Besides revenue forecasting to 2023, our new work shows historical data, growth rates, and market shares. There you discover original analysis, seeing business outlooks and developments. You also get 64 tables, 52 charts, and two interviews with companies.

It can be hard to find data on rare diseases - all that searching. But now you can stay ahead in knowledge for applied oncology, benefiting your research, analyses, and decisions.

+44 20 8123 2220
info@marketpublishers.com

Finding information you need on rare cancer indications just got easier. You save time too. In our study you hear what's going on, also seeing where needs and money lie.

Avoid falling behind then. The following sections show what you get in our new investigation.

Prospects from 2013 for the world market and submarkets

Our new report shows revenue to 2023 for the overall world market. It also shows you individual revenue forecasts to 2023 for five orphan cancer submarkets:

Leukaemia

Multiple myeloma

Lymphoma

Glioma

Other disorders.

How will those segments develop? See which parts can generate most money. Explore biologicals (biologics) - esp. monoclonal antibodies (mAbs) - and small-molecule drugs. There you identify potential for treating tumours (tumors) and other forms of rare cancer.

What's the secret of making money there? Our study gives you a feel, then, for what stimulates and restrains that industry and market. See what's possible and likely.

Find sales predictions by product, too, hearing how they can succeed.

Forecasts from 2013 for orphan anticancer brands

How will orphan cancer drugs perform to 2023 at world level? Our report forecasts revenues of 12 leading drugs and six recently-approved products, including these brands:

Rituxan

+44 20 8123 2220
info@marketpublishers.com

Glivec

Revlimid

Velcade

Cometriq

Stivarga.

There you discover how high sales can go, 2013 to 2023, finding drugs and years with highest predicted growth and revenues. Also you examine competition. You see what's happening, then, understanding challenges, trends, competitors, and opportunities.

Our study also divides its overall world forecast into those for geographical regions.

National markets - what demand for orphan anticancer agents?

From 2013 to 2023 the US, the EU, and Japan offer the greatest opportunity for companies developing and producing therapies for rare cancer indications.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:

US

Japan

Germany, France, UK, Italy, and Spain (EU5), also with EU regional prediction

Brazil, Russia, India, and China (BRIC).

There you find countries with highest revenues and potential sales growth. Our work explains. You explore prospects for treating unusual and under-treated cancers. See effects of existing and future treatments.

Research and development - you assess trends, possibilities, and innovations

+44 20 8123 2220
info@marketpublishers.com

What about R&D - pipelines for new drugs? You assess trends and technologies there, especially in these applications:

Leukaemia

Myelodysplastic syndromes (MDS)

Lymphoma

Multiple myeloma

Glioma.

In 2013 more than 30 agents hold orphan drug status as candidates for treating haematological cancers. Technology for tumours also holds promise. More than 100 orphan anticancer agents exist in mid-to-late stage clinical development, our study finds.

You hear, then, about innovations in oncological R&D. Many molecular pathways and targets exist. Discover progress and find what it means. Our study explains, discussing issues to help your work.

Forces affecting developers, producers, and sellers

Our report shows you issues and events affecting the orphan cancer medicines industry and market from 2013, including these:

Regulations - regional and national

Antibodies, toxin fragments, and other novel immunotherapies

Potential of tyrosine kinase inhibitors

Therapeutic vaccines

Expansions of indications.

+44 20 8123 2220
info@marketpublishers.com

The study discusses other aspects of the technology too, including these:

- Costs of therapy and issues for regulators, governments, and other payers
- Biosimilars and generics as competition for original drugs
- Challenges and opportunities in patient recruitment
- Companion diagnostics and personalised therapies.

There you explore political, economic, social, and technological questions, assessing outlooks for business. Also you gain regulatory insights. See, then, what restrains and what helps that pharma segment. Discover what its present and future hold.

Companies and 2017 market value - what happens next?

From 2013, new treatments hold great potential for investments, medical advances and revenues. Our analysis predicts the world market for orphan cancer drugs will reach $50.3bn in 2017, with high growth from 2013 to 2023.

See what's possible there - the expected gains. Our report shows what technologies and players hold greatest potential. You explore activities of these companies and many others:

- Novartis
- Celgene
- Onyx Pharmaceuticals
- Bristol-Myers Squibb
- Johnson & Johnson
- Merck & Co.

You find 140 organisations covered. You also read two interviews with leaders in the

+44 20 8123 2220
info@marketpublishers.com

industry. Discover what companies think, say, and do, helping you stay ahead.

Information found nowhere else

In particular, then, our investigation gives you these advantages:

> Revenues to 2023 for orphan cancer drugs at world level, with forecasting of 5 submarkets and 18 products - assess potentials for investments and sales
>
> Forecasts to 2023 for 11 national markets in the Americas, Europe, and Asia - investigate countries for revenues and expected growth
>
> Prospects for established competitors and new entrants - explore activities, results, R&D, and outlooks for future success.

Orphan Drugs for Cancer: R&D and Market 2013-2023 gives independent analysis. There you receive business intelligence found only in our work, finding where money lies.

With that report you are less likely to fall behind in knowledge or miss sales opportunity. See there how you could benefit your research, analysis, and decisions. Explore progress and possibilities. Also find how you can save time and get recognition for insight.

Orphan anticancer drugs - assess potentials now, seeing what you can gain

Our new report is for everyone analysing biopharma and orphan diseases. Find sales predications with discussions. Avoid missing out then - please order the report now.

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

6. ORPHAN CANCER DRUGS: R&D PIPELINE 2013

+44 20 8123 2220
info@marketpublishers.com

7. ORPHAN DRUGS IN CANCER: INDUSTRY TRENDS 2013-2023

+44 20 8123 2220
info@marketpublishers.com

8. RESEARCH INTERVIEWS

9. CONCLUSIONS FROM OUR STUDY

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

About

Velcade Faces Significant Competition in Multiple Myeloma 2013-2023

Velcade begins to lose patent protection in major developed markets in 2017. However, between 2013 and then the drug faces significant competition from new multiple myeloma treatments that will restrain revenue growth. Takeda, for example, is developing a second generation proteasome inhibitor that can be dosed orally, compared with via injection for Velcade. This is likely to be launched in the US and EU in 2016, visiongain believes. Celgene also recently received approvalin the US for its third eneration thalidomide derivative Pomalyst. Onyx Pharmaceuticals has also launched a next generation proteasome inhibitor, Kyprolis, although as with Velcade, this drug must be injected.

Towards the middle of this decade, Velcade will also face competition from monoclonal antibody therapies. Unlike many cancer indications, no monoclonal antibodies have yet been approved for treating multiple myeloma. However, promising pipeline therapies include elotuzumab, in development by Bristol-Myers Squibb and AbbVie. As these drugs reach the market, though, Velcade will be facing generic competition. Actavis has already reportedly submitted an ANDA to the FDA for generic bortezomib. Revenue for Velcade will peak in 2016 at $3.11bn, after which it will decline rapidly to $1.17bn in 2023.

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Orphan Drugs for Cancer: R&D and Market 2013-2023
Product link: https://marketpublishers.com/r/O4BD86BB26DEN.html
Price: US$ 2,635.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/O4BD86BB26DEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970